Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japan Again Questions Tamiflu’s Possible Psychiatric Effects

This article was originally published in The Pink Sheet Daily

Executive Summary

Japanese health officials ask Roche subsidiary Chugai to add warnings about giving the drug to teens.

You may also be interested in...



Tamiflu, Relenza Labels Adjusted To Cite Influenza As Potential Cause Of Neuro Events

Roche says label change for Tamiflu reflects growing evidence there is no causal relationship between the drug and neuropsychiatric events.

Tamiflu, Relenza Labels Adjusted To Cite Influenza As Potential Cause Of Neuro Events

Roche says label change for Tamiflu reflects growing evidence there is no causal relationship between the drug and neuropsychiatric events.

FDA Changes Advisory Committee Voting Procedure To Ensure Integrity Of Vote Results

FDA advisory committee members would vote simultaneously rather than sequentially on issues before the panel to avoid influencing each others' votes, according to draft guidance.

Related Content

Topics

UsernamePublicRestriction

Register

PS065789

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel